Free tool
FAERS Monitor: Epysqli
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761340 or its brand name (Epysqli, Eculizumab-Aagh). Reports on generic versions are filed under their own applications.
Reports
27
Serious
24
89% of reports
Hospitalization
11
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use6
- abortion spontaneous2
- condition aggravated2
- death2
- hypertension2
- immunodeficiency2
- maternal exposure during pregnancy2
- acute kidney injury1
- antiphospholipid syndrome1
- atypical haemolytic uraemic syndrome1
- back pain1
- blood pressure increased1
- candida infection1
- cerebrovascular accident1
- conjunctival hyperaemia1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 4 |
| 2025 | 5 |
| 2026 | 18 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,132 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| atypical haemolytic uraemic syndrome | 1 | 960.3 | 140.1 | 239 |
| antiphospholipid syndrome | 1 | 484.9 | 70.8 | 120 |
| conjunctival hyperaemia | 1 | 218.6 | 31.9 | 54 |
| immunodeficiency | 2 | 104.5 | 27.5 | 115 |
| candida infection | 1 | 46.1 | 6.7 | 11 |
| abortion spontaneous | 2 | 38.9 | 10.2 | 41 |
| maternal exposure during pregnancy | 2 | 17.5 | 4.6 | 17 |
| hypertension | 2 | 7.4 | 1.9 | 6 |
| off label useSignal | 6 | 5.3 | 2.6 | 18 |
| condition aggravated | 2 | 5.1 | 1.4 | 3 |
| blood pressure increased | 1 | 5.1 | 0.7 | 0 |
| acute kidney injury | 1 | 5.1 | 0.7 | 0 |
| cerebrovascular accident | 1 | 4.6 | 0.7 | 0 |
| back pain | 1 | 3.4 | 0.5 | 0 |
| death | 2 | 1.8 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.